Johnson & Johnson: Cancer Pain trials

The registry lists 20 Cancer Pain studies with Johnson & Johnson as lead sponsor. 0 are open to participants now and 7 have results posted.

Phase 2 4Phase 3 7Phase 4 7No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Safety and Efficacy Study of Osmotic Release Oral System (OROS) Hydromorphone in Participants With Cancer PainTerminatedNCT01648699Phase 4Results posted
• A Safety and Efficacy Study of JNS024 Extended Release (ER) in Japanese and Korean Patients With Chronic Malignant Tumor-Related Cancer PainCompletedNCT01165281Phase 3Results posted
• Phase 2 Study of Tapentadol Prolonged Release in Cancer Pain ParticipantsCompletedNCT00805142Phase 2Results posted
• A Study to Compare Safety and Efficacy of Osmotic Release Oral Syytem (OROS) Hydromorphone Hydrochloride (HCl) With Morphine Sustain Release (SR) in Participants With Cancer PainTerminatedNCT00803283Phase 3Results posted
• An Efficacy and Safety Study of Hydromorphone Oral Osmotic System (OROS) in Korean Participants With Cancer PainCompletedNCT00766831Phase 4Results posted
• A Dose-Finding Study of Fentanyl (JNS020 QD) 1-Day Transdermal Patch in Participants With Cancer PainCompletedNCT00644787Phase 2/3Results posted
• An Efficacy and Safety Study of Fentanyl (JNS020QD) in Participants With Cancer PainCompletedNCT00641667Phase 3Results posted
• A Study of Safety and Effectiveness of Ultracet in Patients With Chronic Cancer PainCompletedNCT01968018Phase 4
• The Effectiveness of a Patient Self-reported Pain Scoring Tool and a Satisfaction Survey on Cancer Pain ManagementCompletedNCT01829828
• Fentanyl Matrix Application for Cancer Pain: Multicenter, Prospective, Observational StudyCompletedNCT01816503
• Study to Evaluate Effectiveness and Tolerability of OROS Hydromorphone for Cancer Pain Treatment in Korean PatientsCompletedNCT01621100Phase 4
• Case-control Study- Cancer Pain: Uncontrolled Pain as Depression Development Predictor in Oncologic Patients (Fentanyl)CompletedNCT01402830
• A Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Cancer-related PainCompletedNCT00929188Phase 2
• An Efficacy and Safety Study of Low-dose Transdermal Therapeutic System (TTS)-Fentanyl D-Trans in Taiwan Participants With Cancer PainCompletedNCT00771199Phase 4
• A Study to Evaluate the Safety and Effectiveness of Fentanyl-TTS Compared to Weak Opioids in Patients With Moderate to Severe Chronic Cancer Pain Previously Treated With NSAIDS (Non-steroidal Anti-inflammatory Drugs).CompletedNCT00576017Phase 4
• A Repeated-Dose Evaluation of Use of a Pain Relieving Drug and Safety of OROS Hydromorphone HCI in Patients With Chronic Cancer PainCompletedNCT00411034Phase 3
• Safety and Tolerability of Long-term Administration of OROS Hydromorphone HCI (Slow Release) in Cancer PainCompletedNCT00410787Phase 3
• A Study of OROS Hydromorphone HCL vs Morphine in Cancer Pain Patients.CompletedNCT00410540Phase 3
• Evaluation of the Efficacy and Safety of Fentanyl Delivered by Adhesive Skin Patch in Out-Patients With Chronic Cancer PainTerminatedNCT00236327Phase 4
• Phase II Clinical Trial of Fentanyl Transdermal Matrix Patch, in the Management of Cancer Pain- Assessment of Effectiveness, Safety and Pharmacokinetics -CompletedNCT00216658Phase 2